| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney DiseaseNCT02836574 | Prokidney | Phase 2 | Completed | 2023-12Actual |
| Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 InfectionNCT02859961 | CytoDyn, Inc. | Phase 2, Phase 3 | Completed | 2020-09-16Actual |
| Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid LeukemiaNCT02873338 | Jazz Pharmaceuticals | Phase 2 | Completed | 2019-06Actual |
| Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PADNCT02887859 | HUMA | Phase 2 | Completed | 2020-12Actual |
| Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative ColitisNCT02895100 | PTGX | Phase 2 | Terminated | 2018-03-26Actual |
| Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency ObesityNCT02896192 | RYTM | Phase 3 | Completed | 2020-05-25Actual |
| Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)NCT02912260 | MDGL | Phase 2 | Completed | 2017-10-25Actual |
| Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's DiseaseNCT02914561 | LKFT | Phase 3 | Completed | 2022-11-11Actual |
| Filgotinib in Long-Term Extension Study of Adults With Crohn's DiseaseNCT02914600 | LKFT | Phase 3 | Terminated | 2023-08-01Actual |
| Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut AllergyNCT02920021 | ANAB | Phase 2 | Completed | 2018-03-30Actual |
| A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)NCT02942004 | SUPN | Phase 3 | Completed | 2017-09-24Actual |
| A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)NCT02942017 | SUPN | Phase 3 | Completed | 2017-09-17Actual |
| Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromNCT02952508 | CLRB | Phase 2 | Active not recruiting | 2026-06-22Estimated |
| Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenNCT02968004 | OPK | Phase 3 | Completed | 2019-08Actual |
| Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of GastroparesisNCT02970968 | Vanda Pharmaceuticals | Phase 2 | Completed | 2018-11Actual |
| Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)NCT02973789 | NovoCure GmbH | Phase 3 | Completed | 2024-09-24Actual |
| An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label StudyNCT02990858 | CytoDyn, Inc. | Phase 2, Phase 3 | Terminated | 2022-06Actual |
| A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) SyndromeNCT03005327 | X4 Pharmaceuticals | Phase 2 | Completed | 2022-06-16Actual |
| Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular TraumaNCT03005418 | HUMA | Phase 2, Phase 3 | Completed | 2023-09-19Actual |
| Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityNCT03013543 | RYTM | Phase 2 | Completed | 2022-03-01Actual |
| QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder CancerNCT03022825 | IBRX | Phase 2, Phase 3 | Active not recruiting | 2024-10-01Actual |
| Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)NCT03028350 | Cumberland Pharmaceuticals | Phase 2 | Completed | 2023-04-25Actual |
| INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted InfectionsNCT03037164 | Cerus Corporation | Phase 3 | Completed | 2026-04-29Actual |
| Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)NCT03038022 | MDGL | Phase 2 | Completed | 2018-01-15Actual |
| Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDDNCT03051256 | RLMD | Phase 2 | Completed | 2019-07-30Actual |
| Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal TreatmentNCT03059992 | SCYX | Phase 3 | Completed | 2023-08-25Actual |
| Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSDNCT03062540 | Tonix Pharmaceuticals, Inc. | Phase 3 | Terminated | 2018-07-27Actual |
| Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaNCT03070392 | Immunocore Ltd | Phase 2 | Completed | 2020-10-13Actual |
| Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & NeckNCT03083873 | IOVA | Phase 2 | Completed | 2022-08-08Actual |
| ABX464 in Subjects With Moderate to Severe Active Ulcerative ColitisNCT03093259 | ABVX | Phase 2 | Completed | 2018-07-25Actual |
Trial details
- Registry ID
- NCT02836574
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02859961
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT02873338
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02887859
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02895100
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02896192
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02912260
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02914561
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02914600
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02920021
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02942004
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02942017
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02952508
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02968004
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02970968
- Phase
- Phase 2
Trial details
- Registry ID
- NCT02973789
- Phase
- Phase 3
Trial details
- Registry ID
- NCT02990858
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT03005327
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03005418
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT03013543
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03022825
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT03028350
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03037164
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03038022
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03051256
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03059992
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03062540
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03070392
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03083873
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03093259
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.